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This case–control study investigates the potential chemoprophylactic properties of non-steroidal anti-
inflammatory drugs (NSAIDs) on the incidence of cutaneous melanoma (CM). Data were extracted from the
Dutch PHARMO pharmacy database and the PALGA pathology database. Cases had a primary CM between 1991
and 2004, wereX18 years, and were observed for 3 years in PHARMO before diagnosis. Controls were matched
for date of birth, gender, and geographical region. NSAIDs and acetylsalicylic acids (ASAs) were analyzed
separately. Adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated using multivariable
logistic regression, and the results were stratified across gender. A total of 1,318 CM cases and 6,786 controls
were eligible to enter the study. CM incidence was not significantly associated with ever ASA use (adjusted OR:
0.92, 95% CI: 0.76–1.12) or ever non-ASA NSAID use (adjusted OR: 1.10, 95% CI: 0.97–1.24). However, continuous
use of low-dose ASAs was associated with a significant reduction of CM risk in women (adjusted OR: 0.54,
95% CI: 0.30–0.99) but not in men (OR: 1.01, 95% CI: 0.69–1.47). A significant trend (P¼ 0.04) from no use,
non-continuous use to continuous use was observed in women. Continuous use of low-dose ASAs may be
associated with a reduced incidence of CM in women, but not in men.
Journal of Investigative Dermatology (2009) 129, 2620–2627; doi:10.1038/jid.2009.201; published online 9 July 2009
INTRODUCTION
Cutaneous melanoma (CM) is a growing health problem, as
CM incidence rates are steadily rising in both Europe (de
Vries et al., 2003) and the United States (Cancer Facts
and Figures 2007, accessed on 5 January 2009, on http://
www.cancer.org). However, mortality rates seem to have
leveled off, probably because of increased awareness
resulting in early detection of CM (de Vries and Coebergh,
2004). Although local CM is generally successfully treated
with surgery, for metastatic disease therapeutic results remain
disappointing (de Vries et al., 2003; Eigentler et al., 2003).
Consequently, focus of the melanoma research has shifted
from therapy to prevention and early detection.
Chemoprevention may complement current preventive
measures and is defined as the use of natural or synthetic
agents to prevent, reverse, suppress, or delay pre-malignant
lesions from progressing into invasive cancer (Demierre, 2006).
Non-steroidal anti-inflammatory drugs (NSAIDs) have shown
promising results in various solid cancers (Harris et al., 2005)
and may have chemopreventive potential in CM (Francis et al.,
2006). In vitro studies in melanoma cell lines have shown that
NSAIDs can induce apoptosis (Vogt et al., 2001; Bundscherer
et al., 2008) and inhibit tumor growth and invasion (Denkert
et al., 2001; Chiu et al., 2005; Bundscherer et al., 2008).
The proposed anticancer mechanism of NSAIDs is inhibition
of cyclooxygenase-2 (COX-2). This enzyme is inducible by
inflammatory stimuli, is overexpressed in different neoplasms,
and is probably linked to carcinogenesis through various
mechanisms, for example, angiogenesis, apoptosis, inflamma-
tion, and immune function (Xu, 2002; Harris et al., 2005).
However, NSAIDs may inhibit cancer through various COX-
independent pathways as well (Marx, 2001; Elwood et al., 2009).
This could be of particular importance in CM, as NSAIDs inhibit
the growth of CM cell lines independent of COX-2 (Vogt et al.,
2001; Xu, 2002; Chiu et al., 2005; Bundscherer et al., 2008; Lee
et al., 2008), and COX-2 is not consistently expressed in CM
(Denkert et al., 2001; Vogt et al., 2001; Goulet et al., 2003;
Nettelbeck et al., 2003; Kuzbicki et al., 2006; Lee et al., 2008).
Thus far, most of the epidemiological studies assessing the
chemoprophylactic effects of NSAIDs on CM incidence focus
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on acetylsalicylic acids (ASAs). A randomized controlled trial
(RCT) and a large cohort study did not find an association
between low- or high-dose aspirin use and CM incidence (Cook
et al., 2005; Jacobs et al., 2007). Studies investigating a possible
association of CM and non-ASA NSAIDs are limited. Recently, a
large cohort study did not observe an association with either
ASA or non-ASA NSAIDs on CM incidence (Asgari et al., 2008).
However, two smaller epidemiological studies suggested a
reduced risk on CM incidence and progression in NSAID users
(Harris et al., 2001; Ramirez et al., 2005). Therefore, the potential
chemoprophylactic properties of NSAIDs remain unclear due to
heterogeneity in study design and conflicting results.
The objective of this study was to investigate a possible
protective effect of ASA and non-ASA NSAIDs on CM
incidence in a large population-based sample by linking the
Dutch pathology registry with a pharmacy database.
RESULTS
Study population
The ascertainment of the cases and controls has been
described previously (Koomen et al., 2007). Briefly, of the
3,561 subjects who were registered in PHARMO (Institute for
Drug Outcome Research) and had a systemized nomencla-
ture of medicine (SNOMED) code ‘melanoma’ in PALGA (The
Nationwide Network and Registry of Histo- and Cytopathology
in The Netherlands), 1,318 (37.0%) cases met the eligibility
criteria (Figure 1). Patients were mostly excluded because the
registration periods in PHARMO and PALGA did not match,
leading to incomplete pharmacy records in PHARMO in the
3-year observation period before CM diagnosis. Of the 16,133
controls matched for gender, age, and geographical region,
6,786 (42.1%) met the inclusion criteria.
About 60% of the study population was female, with a mean
age of 55 years (Table 2). Compared with the controls, cases
had a significantly higher number of unique non-melanoma
International Classification of Disease (ICD) diagnoses (0.71
vs 0.61, P¼ 0.04), which was confirmed in men, but not in
women. Also, cases had a higher number of unique medica-
tions prescribed (7.53 unique Anatomical Therapeutical
Chemical Classification System (ATC) codes vs 6.93,
Po0.01), which was confirmed in both men and women. As
reported earlier, women with melanoma used more estrogens
compared with the control population (31.6 vs 24.8%,
P¼o0.001) (Koomen et al., 2009).
PALGA
n = 9×106
PHARMO
n = 24×106
Class
n = 3,561
Cases
n = 1,371
n = 53
No matched
controls
included
Cases
n = 1,318
1Cases excluded Total n = 2,243
1 = Entry date missing 1 = Entry date missing
2 = Age at diagnosis <18 years 2 = Age at diagnosis <18 years
3 = OP 3-year before CM incomplete 3 = OP 3 years before index date incomplete
4 = possible CM patient (ICD code ‘CM’)4 = CM not pathologically confirmed
5 = Primary CM before 1991
6 = No Cutaneous MM (e.g., eye)
7 = in situ CM
8 = No matched controls included
3.5
0.8
63
15
4.1
9.1
2.0
2.4
2Controls excluded Total n =9347
n = 640
n = 30
n = 8673
n = 4
100(%)
6.8
0.3
93
0.04
100(%)
Total: n = 8,104 Controls
n = 6,786
9,347 controls
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Controls
n = 16,133
Matched on:
1. Gender
2. Age
3. Geographic region
2,190 cases
excluded 1
n = 78
n = 19
n = 1408
n = 343
n = 93
n = 205
n = 44
n = 53
Figure 1. Flow chart of study population. CM, cutaneous melanoma; OP, observation period; MM, malignant melanoma; ICD, International Classification of
Disease.
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ASA use and CM incidence
More than 40% of the total NSAID use consisted of ASA use
(Table 1). The proportion of CM patients who used ASA was
comparable with the controls, except for high-dose ASAs
(Table 2). Female cases were significantly less likely to be a
continuous user of low-dose ASAs than their matched
controls (1.7 vs 3.1%, P¼0.03). In men, no significant
difference in the distribution of ASA exposure was observed.
After adjusting for age, gender, year of diagnosis, prior use of
statins and estrogens, and unique number of ICD and ATC
codes in a multivariable model, none of the ASA exposure
variables were significantly associated with CM incidence in
the total study population and in men (Table 3). However, in
women, continuous use of low-dose ASA for 3 years was
associated with a reduced risk of developing a CM of almost
50% (adjusted OR: 0.54, 95% CI: 0.30–0.99). In addition, in
women, there was a significant dose–response trend for no
use, non-continuous use, and continuous use (P-value for
trend¼0.04).
Non-ASA NSAID use and CM incidence
The most commonly dispensed non-ASA NSAIDs were
diclofenac (20.5%), ibuprofen (14.5%) and naproxen
(10.0%) (Table 1). Female and, to a lesser extent, male CM
patients were more likely to have ever used non-ASA NSAIDs
compared with controls (Table 2). Of the non-ASA NSAID
users, the overwhelming majority used o600 pills during 3
years and only 2.3 and 2.9% of cases and controls,
respectively, used more than 600 pills. In the distribution of
the categories of the cumulative number of pills, the only
significant difference was observed in the lowest category of
1–600 pills for the total study population and for women.
In the multivariable models that adjusted for multiple
confounders, no significant associations were found,
although relatively low non-ASA NSAID exposure (1–600
pills) was borderline significantly associated with a modest
increase in CM risk (OR: 1.12, 95% CI: 0.98–1.23, Table 3).
In further subgroup analysis, the use of 1–4 prescriptions of
non-ASA NSAIDs in 3 years was significantly associated with
a marginally increased risk of CM (OR: 1.15, 95% CI:
1.01–1.30, data not shown). Higher levels of exposure
appeared to be protective for all subgroups, but none of
these associations were significant (Table 3).
DISCUSSION
NSAID use and risk of CM
Continuous use of low-dose ASAs during 3 years was
associated with a reduced likelihood of developing CM in
women but not in men.
In contrast, none of the non-ASA NSAID variables were
significantly associated with the risk of having a CM in the
multivariable model (Table 3). However, infrequent use of
pills (1–600 pills in 3 years) was significantly associated with
the incidence of CM in an univariate analysis (Table 2), but
this was not significant in the multivariable model after
adjusting for health-care consumption (Table 3), suggesting
that this and the possible other confounders affected the
univiarate model. Interestingly, a similar association has
been reported in a case–control study in prostate cancer
(Perron et al., 2003). This illustrates that use of health
care may be an important confounder in pharmaco-
epidemiological studies.
The use of larger quantities of non-ASA NSAIDs (4600
pills in 3 years) seemed to be protective for CMs but did not
reach significance, which could be explained, in part, by a
relatively short time of observation (3 years), limited sample
size in this subgroup (o225 patients), and/or that non-ASA
NSAIDs were administered as analgetics (the prescribed
frequency of the use by physicians was most often ‘when
Table 1. ATC codes and corresponding NSAID1
ASAs ATC code % of total2
Acetylsalicylic acid B01AC06/N02BA01 22.5
Carbasalate calcium B01AC08/N02BA15 19.1
ASA use 41.6
Non-ASA NSAIDs ATC code % of total2
Diclofenac M01AB05 20.5
Ibuprofen M01AE01 14.5
Naproxen M01AE02 10.0
Rofecoxib3 M01AH02 3.0
Diclofenac, combinations M01AB55 2.5
Indometacin M01AB01 2.3
Meloxicam M01AC06 1.6
Piroxicam M01AC01 1.2
Nabumetone M01AX01 1.0
Ketoprofen M01AE03 0.4
Celecoxib M01AH01 0.3
Sulindac M01AB02 0.3
Tiaprofenic acid M01AE11 0.2
Aceclofenac M01AB16 0.1
Etoricoxib M01AH05 0.1
Flurbiprofen M01AE09 0.1
Tenoxicam M01AC02 0.1
Dexibuprofen M01AE14 o0.1
Dexketoprofen M01AE17 o0.1
Diflunisal N02BA11 o0.1
Tolfenamic acid M01AG02 o0.1
Metamizole sodium N02BB02 o0.1
Non-ASA NSAID use 58.4
ASAs, acetylsalicylic acids; ATC, anatomical therapeutic chemical
classification system; NSAIDs, non-steroidal anti-inflammatory drugs.
1All available NSAID ATC codes were included in the study. Presented
are ATC codes corresponding with 1 or more prescription among cases
and controls.
2Percentage (%) of the total 22,279 prescriptions among cases and
controls.
3Withdrawn from the Dutch market in 2004.
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Table 2. Study group characteristics
Total group Males Females
Cases
(n=1,318)
Controls
(n=6,786) P-value
Cases
(n=540)
Controls
(n=2,714) P-value
Cases
(n=778)
Controls
(n=4,072) P-value
Gender 1
Male 540 (41.0%) 2,714 (40.0%)
Female 778 (59.0%) 4,072 (60.0%) 0.51
Age at index date2
Years 55.3 (±15.9) 55.9 (±15.5) 0.18 57.7 (±14.6) 58.0 (±14.2) 0.72 53.6 (±16.5) 54.6 (±16.1) 0.13
Total unique diagnoses2
N 0.71 (±1.52) 0.61 (±1.55) 0.04 0.84 (±1.8) 0.66 (±1.6) 0.023 0.62 (±1.3) 0.59 (±1.5) 0.55
Total unique medications prescribed2
N 7.53 (±6.49) 6.93 (±6.78) o0.01 6.95 (±6.9) 6.24 (±6.3) 0.033 7.93 (±6.2) 7.39 (±7.0) 0.033
Estrogen use1
Ever use 246 (18.7%) 1,009 (14.9%) — — 246 (31.6%) 1,009 (24.8%)
Never use 1,072 (81.3%) 5,777 (85.1%) o0.01 — — 532 (68.4%) 3,063 (75.2%) o0.01
Statin use1
Ever use 115 (8.7%) 574 (8.5%) 75 (13.9%) 309 (11.4%) 40 (5.1%) 265 (6.5%)
Never use 1,203 (91.3%) 6,212 (91.5%) 0.75 465 (86.1%) 2,405 (88.6%) 0.10 738 (94.9%) 3,807 (93.5%) 0.15
ASA use
Never use 1,137 (86.3%) 5,853 (86.3%) 435 (80.6%) 2,219 (81.8%) 702 (90.2%) 3,634 (89.2%)
Ever use 181 (13.7%) 933 (13.7%) 0.99 105 (19.4%) 495 (18.2%) 0.51 76 (9.8%) 438 (10.8%) 0.41
Type of ASA use
Never use 1,137 (86.3%) 5,853 (86.3%) 435 (80.6%) 2,219 (81.8%) 702 (90.2%) 3,634 (89.2%)
Low-dose,
non-continuous use
76 (5.8%) 455 (6.7%) 0.24 42 (7.8%) 239 (8.8%) 0.53 34 (4.4%) 216 (5.3%) 0.28
Low-dose,
continuous use
61 (4.6%) 329 (4.8%) 0.75 48 (8.9%) 204 (7.5%) 0.28 13 (1.7%) 125 (3.1%) 0.03
High-dose use 44 (3.3%) 149 (2.2%) 0.02 15 (2.8%) 52 (1.9%) 0.19 29 (3.7%) 97 (2.4%) 0.04
Non-ASA NSAIDs use
Never use 700 (53.1%) 3,862 (56.9%) 304 (56.3%) 1,598 (58.9%) 0.27 396 (50.9%) 2,264 (55.6%)
Ever use 618 (46.9%) 2,924 (43.1%) 0.01 236 (43.7%) 1,116 (41.1%) 382 (49.1%) 1,808 (44.4%) 0.02
Cumulative no. of pills
No use 700 (53.1%) 3,862 (56.9%) 304 (56.3%) 1,598 (58.9%) 396 (50.9%) 2,264 (55.6%)
1–600 588 (44.6%) 2,728 (40.2%) o0.01 226 (41.9%) 1,051 (38.7%) 0.20 362 (46.5%) 1,677 (41.2%) o0.01
601–1,000 12 (0.9%) 92 (1.4%) 0.29 3 (0.6%) 31 (1.1%) 0.26 9 (1.2%) 61 (1.5%) 0.63
41,000 18 (1.4%) 104 (1.5%) 0.86 7 (1.4%) 34 (1.3%) 0.85 11 (1.4%) 70 (1.7%) 0.74
ASA, acetylsalicylic acids; NSAIDs, non-steroidal anti-inflammatory drugs.
1Number of cases and controls presented, ±SD? tested for statistical difference with w2-test.
2Mean value presented, tested for statistical difference with t-test.
3Equal variances not assumed according to Levene’s test for equality of variances.
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needed’); thus implying non-continuous exposure. On
account of small numbers, separate analyses for selective
COX-2 inhibitors could not be carried out.
The observed difference in chemoprophylactic effects
between non-ASA NSAIDs and ASAs may be dependent on
the patterns of use or on a different mechanism of action.
First, low-dose ASAs are most commonly prescribed as daily
cardiovascular preventive drugs, whereas non-ASA NSAIDs
and high-dose ASAs are commonly used irregularly as
analgetics. Second, ASAs may have additional anti-cancer
effects in comparison with non-ASAs, such as inhibition of
thrombocyte aggregation (Rickles and Falanga, 2001), or
effects of cancer-related systems such as apoptosis, NF-eˆB,
DNA repair systems, oxidative stress, or mitochondrial
calcium uptake (Elwood et al., 2009).
We did not find a reduced CM incidence among overall
non-ASA NSAID or ASA users, which is in accordance with
three large observational studies. A large cohort study of
regular and high-dose ASA (4325mg) exposure observed no
protective effect on CM (Jacobs et al., 2007). A second cohort
confirmed the absence of an association between ASA or
non-ASA NSAID use and CM incidence (Asgari et al., 2008).
This study, however, has several limitations, that is, low-dose
aspirin exposure was excluded in subgroup analyses, B40%
of cases were CM in situ, and stratification across gender was
not carried out. Our results, showing an association of low-
dose ASA use in women with CM is in contrast with an RCT
among females for whom low-dose aspirin use (100mg every
other day) for an average of 10 years did not affect CM
incidence (68 vs 70 incident cases, P¼ 0.87) (Cook et al.,
2005). This study however was limited by a small number of
CM cases, non-continuous exposure, and was not popula-
tion-based.
In other malignancies, multiple studies investigating the
chemopreventive properties of ASA and non-ASA NSAIDs
have been published. A review showed that in colorectal,
breast, and lung cancer, the risk reductions by non-ASA
NSAIDs and ASAs were comparable (Harris et al., 2005),
which contradicts our results that suggest a different effect.
Results of a case–control study on prostate cancer, however,
were comparable: prolonged use of ASAs showed a
protective effect, whereas use of non-ASA NSAIDs did not
(Perron et al., 2003). In lung (Harris et al., 2002), breast
(Harris et al., 2006), and prostate (Perron et al., 2003) cancer,
exposure to regular or high-dose use of ASAs did, but
exposure to low-dose ASA did not, decrease the incidence of
these cancers, which is not in line with our findings in CM
patients.
Table 3. ASA/NSAID use and cutaneous melanoma
Total Males Females
Variable n Adjusted OR1 95% CI n Adjusted OR1 95% CI n Adjusted OR1 95% CI
ASA use
Overall exposure
Never ASA use 6,990 1.00 Referent 2,654 1.00 Referent 4,336 1.00 Referent
ASA use 1,114 0.92 0.76–1.12 600 0.92 0.69–1.21 514 0.90 0.68–1.19
Use of ASA
Never Use 6,990 1.00 Referent 2,654 1.00 Referent 4,336 1.00 Referent
Low dose o3 years2 531 0.77 0.58–1.01 281 0.72 0.49–1.06 250 0.82 0.55–1.22
Low dose 3 years2 390 0.87 0.64–1.18 252 1.01 0.69–1.47 138 0.54 0.30–0.99
High dose (ever)3 193 1.35 0.96–1.92 67 1.34 0.74–2.43 126 1.37 0.89–2.11
Non-ASA NSAIDs
Overall exposure
Never NSAID use 4,562 1.00 Referent 1,902 1.00 Referent 2,660 1.00 Referent
NSAID use 3,542 1.10 0.97–1.24 1,352 1.04 0.86–1.26 2,190 1.13 0.96–1.34
Cumulative pills
0 4,562 1.00 Referent 1,902 1.00 Referent 2,660 1.00 Referent
1–600 3,316 1.12 0.98–1.23 1,277 1.06 0.87–1.27 2,039 1.15 0.98–1.36
601–1,000 104 0.67 0.36–1.23 34 0.46 0.14–1.51 70 0.82 0.40–1.69
41,000 122 0.89 0.53–1.43 41 0.96 0.42–2.21 81 0.88 0.46–1.69
ASA, acetylsalicylic acids; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs; OR, odd ratio.
1Adjusted for age, sex (only in total group), year of diagnosis, the use of statins resp. estrogens (only in females), the total of different medical diagnoses, total
of different medications prescribed, and the interaction term between the latter two.
2Use of 30–100mg acetylsalicylic acid per unit (X990 pills is considered 3 years–continuous use).
3Use of 4100mg acetylsalicylic acid per unit.
Bold values are statistically significant.
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However, comparing the results of studies assessing the
chemoprophylactic effect of NSAIDs is challenging because
studies differ in several important ways such as ascertainment
of drug exposure (for example, self-reported or pharmacy
database), definition of exposure, type of NSAID (ASA or non-
ASA), dose, duration, patterns of use (for example, sporadic,
intermittent, chronic), drug adherence, study population (for
example, general population, cohorts from tertiary centers),
melanoma (for example, invasive or in situ CM), sample size,
and subgroup analyses (that is, stratification across gender). A
pivotal unresolved problem is the definition of the dosage of
NSAID, which could have chemoprophylactic effects.
Gender differences
Stratification across gender showed a gender difference in
favor of women, especially for continuous use of low-dose
ASAs. This apparent discrepancy between men and women is
not well understood and may be explained by pharmacolo-
gical and melanoma differences. Pharmacodynamics and
pharmacokinetics of ASA differ between men and women:
the effect on platelets that differs across gender and women
achieve higher concentrations with equal doses being
administrated (Levin, 2005). As ASA may influence oxidative
stress, the gender difference in antioxidant enzymes may
have a role (May, 2007). Remarkably, a recent RCT
investigating antioxidant supplementation showed an in-
crease in the incidence of CM in women, but not in men
(Hercberg et al., 2007). Another explanation may be that
biology of melanoma itself may not be comparable in men
and women, as CM survival differs significantly across gender
when adjusted for other prognostic factors (de Vries et al.,
2008; Lasithiotakis et al., 2008). Differences in adherence to
cardiovascular drugs, however, are not likely to explain the
observed gender differences (Kulkarni et al., 2006).
Interestingly, we previously reported a gender difference
in the effects of statins with regard to CM incidence and
progression using the same study population (Koomen et al.,
2007). Future (epidemiological) studies are warranted to
explore CM gender differences.
Strengths and weaknesses
This is the largest population-based study that investigates the
effect of NSAID use on CM incidence in more than 1,350
cases. The CM cases were confirmed by a pathology report,
and drug exposure was prospectively assessed by a highly
reliable pharmacy database. (Herings R (1993). PHARMO: a
record linkage system for postmarketing surveillance of
prescription drugs in the Netherlands. Thesis in pharmaco-
epidemiology and pharmacotherapy. Utrecht University). In
PHARMO, detailed information on drug use was available,
such as the number of dispenses, the number of dispensed
pills, and dosage. As the dosages (in World Health
Organization (WHO)’s Defined Daily Doses) of NSAIDs vary
largely between the indications for which they are pre-
scribed, we were not able to include this information.
Furthermore, as a large proportion of the NSAIDs are used
as analgetics ‘on demand,’ no data were available regarding
the duration of use for these types of NSAIDs. Therefore,
duration of use could not be included in the analyses, except
based on the number of pills prescribed. As several NSAIDs
are available over the counter without a prescription, the
actual use of NSAIDs is underestimated. Therefore, if this
would influence our results, it is most likely that this would
produce bias toward the null. However, this misclassification
is likely to be equal among cases and controls; hence, bias is
likely to be minimal. In this study, NSAID use was
ascertained in the 3 years before CM diagnosis, which may
have been too short to detect the effect of NSAID exposure
(Harris et al., 2005). However, increasing the observation
period to 5 years decreased the sample size substantially
(from 1,318 to 931 CM cases). Although a proxy for health-
care consumption was included in the multivariable model,
surveillance bias may still have affected our results. Informa-
tion on lifestyle factors such as sun exposure was not
available, but the confounding effect of sun exposure on
NSAID use seems to be limited.
In conclusion, long-term use of (low-dose) ASA was
associated with a reduced risk of CM in women, but not in
men. Future observational and ultimately interventional
clinical studies are needed to confirm these findings.
MATERIALS AND METHODS
Setting
This study was designed as a case–control study, using population-
based data from two Dutch databases. PHARMO is a network of
linked databases including a pharmacy database containing more
than two million Dutch residents, representing 12% of the total
Dutch population. The residents were included regardless of the type
of insurance (http://www.pharmo.nl/, PHARMO RLS Network,
accessed on 5 January 2009). An individual enters the PHARMO
database when obtaining the first prescription in a PHARMO
pharmacy, and is observed until the last prescription. As most
patients in The Netherlands visit a single pharmacy, drug dispensing
records are virtually complete (Lau et al., 1997). The prospectively
gathered computerized drug dispensing records contain the date of
dispense, type, quantity, dosage form, strength, and daily dose of the
prescribed drug.
PHARMO was linked to PALGA, the Dutch registry of
histopathology and cytopathology, using a variation of a reliable
probabilistic algorithm. (Herings R (1993). PHARMO: a record
linkage system for postmarketing surveillance of prescription drugs
in the Netherlands. Thesis in pharmaco-epidemiology and pharma-
cotherapy. Utrecht University) PALGA contains abstracts of all
Dutch pathology reports encrypted with patient identification and
diagnostic terms in scope with the SNOMED classification, and
reached 100% participation from 1990 onward, and therefore is the
basis of the Dutch Cancer Registry (Casparie et al., 2007).
The protocol of this study was approved by the scientific and
privacy committees of both PALGA and PHARMO, and was granted
exempt status by the ethics board of the Leiden University Medical
Centre.
Study population
Cases were defined as individuals with a CM diagnosis in PALGA
between 1 January 1991 and 14 December 2004 and who were also
registered in PHARMO in the same period. The end point of the
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observation period was defined as the date of CM diagnosis (index
date). For each case, two investigators (AJ, ERK) extracted final
diagnosis, date, and Breslow’s depth from the PALGA pathology
reports with high accordance (k40.85) (Koomen et al., 2007). Cases
were excluded if, in PALGA, the date of primary CM diagnosis was
before the age of 18 years or before 1 January 1991, the primary
melanoma was not pathologically confirmed, was in situ, or was
non-cutaneous, or in PHARMO, the date of entry was unknown,
gender was unknown, or time of observation before CM diagnosis
was o3 years (Figure 1).
For every eligible case, an average of five controls matched for
gender, date of birth (±2 years), and geographic region (B100
regions based on clusters of local pharmacies) were sampled from
PHARMO. To calculate the time of observation for the controls, they
were assigned the index date of the matched case to be able to
determine the 3-year observation period. Controls were excluded if,
in PHARMO, the date of entry was unknown, they were younger
than 18 years at the index date, the time of observation before index
date was o3 years, or a diagnosis of melanoma was recorded
according to the ICD9-CM in the hospital linkage database of
PHARMO (Figure 1).
Drug exposure
For all cases and controls, systemic NSAID use, restricted to the
3-year observation period before the index date, was extracted from
the PHARMO database using the ATC codes of the WHO. All
NSAIDs, including ASAs, available in The Netherlands were
included (Table 1). Drug dispenses containing o7 pills were
excluded (for example, after a dental extraction), but weekly
prescribed NSAIDs were included (for example, weekly pharmacy
deliveries to nursery homes).
ASAs were investigated separately from non-ASA NSAIDs
because, next to COX-2 inhibition, they inhibit thrombocyte
aggregation, which has been linked to carcinogenesis (Rickles and
Falanga, 2001). Furthermore, ASAs are almost exclusively prescribed
for long-term continuous use and not for intermittent use as an
analgetic, in contrast with non-ASA NSAIDs.
ASA use
Among all users, ASA use was categorized by prescribed dosage.
Individuals who used low-dose ASA (30–100mg daily) were
categorized into continuous (that is, use of X990U of ASA during
the observation period of 3 years or 1,095 days) and non-continuous
users. Higher doses of ASA (X100mg) were dispensed far less
frequently and were mostly prescribed for on-demand use, suggest-
ing temporary use as an analgetic. It was not possible to extract
continuous users from this group of high-dose ASA users because of
the low cumulative quantities of pills used during the observation
period. Therefore, all users of high-dose ASA were analyzed
separately.
Non-ASA NSAID use
None-ASA NSAIDs such as, ibuprofen and diclofenac, were
prescribed irregularly, with a wide variation of daily prescribed
doses, and to be used on demand. Therefore, assumptions for
continuous or non-continuous use could not be made, and
categorization was limited to the number of pills prescribed. For
the categories of cumulative number of pills, the cutoff values were
chosen to reflect levels of exposure: non-users, individuals who were
likely to be exposed for o2/3 years of the observation period of 3
years (1–600 pills during 1,095 days), individuals using on average
more than one pill daily in 3 years (41,000 pills) and an
intermediate group.
Potential confounders
Ever use of drugs related to progression and the development of CM,
such as statins (Koomen et al., 2007) and estrogens (Koomen et al.,
2009), were considered possible confounders. The use of heparins,
fibrates, and other lipid-lowering drugs was also recorded. However,
the number of individuals using these drugs was too small (o1.0%)
to be used in further analysis. To adjust for a possible surveillance
bias (that is, patients who seek medical care are more likely to be
diagnosed with other disease including CM), a proxy of health-care
and pharmacy-seeking behavior was created by calculating the total
number of unique ATC codes (excluding all NSAIDs) and the total
number of unique ICD9-CM codes (that were primary discharge
diagnosis after hospitalization), which were both recorded in the
database in the 3 years before the index date. The ICD code for
melanoma found for each case was not included in the total number
of unique ICD codes to avoid overmatching. Both confounders
proved to be significant in all multivariable analyses carried out and
also showed a significant interaction with each other. This
interaction term was added in the multivariable analysis (Po0.01).
Statistical analysis
A w2-test was used to test for statistical differences between
categorical variables, for continuous variables a Student’s t-test or a
Mann–Whitney U-test was used as appropriate. A multivariable
logistic regression model was used to calculate adjusted ORs and
95% CIs to analyze the association between dependent CM incidence
and NSAID use and its defined categorizations of exposure.
As CM development, progression, and survival, as the effect of
potential chemoprophylactic drugs, may differ across gender (Levin,
2005; Koomen et al., 2007; de Vries et al., 2008; Lasithiotakis et al.,
2008), a pre-specified separate analysis for men, women, and for the
total group was carried out.
All statistical tests were two-sided, with a rejection of the null
hypothesis at Po0.05. All statistical analyses were carried out using
SPSS 14.0 (0.2) (SPSS, Chicago, IL).
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